Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity:Rhinomed Limited (ASX: RNO)
ACN:107 903 159
We (the entity) give ASX the following information.
Part 1 -‐ All issuesYou must complete the relevant sections (attach sheets if there is not enough space).
Ordinary Shares (RNO)
1 +Class of +securities issued or to be issued
122,135,100 Ordinary Shares (RNO)
Number of +securities issued or to be issued (if known) or maximum number which may be issued
Fully Paid Ordinary Shares (RNO)
Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if
+convertible securities, the conversion price and dates for conversion)
Ordinary shares rank equally with existing quoted ordinary shares.
Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?
If the additional securities do not rank equally, please state:
the date from which they do
the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
122,135,000 Shares: $0.018 per Share. 100 Shares: $0.10 per Share
Issue price or consideration
122,135,000 Shares: Private Placement raising
$2,198,430 before costs.
100 Shares: Private Placement issued under Cleansing Prospectus.
Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)
Yes
6aIs the entity an +eligible entity that has obtained security holder approval under rule 7.1A?
If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i
8th November 2016
6b The date the security holder resolution under rule 7.1A was passed
122,135,100
6c Number of +securities issued without security holder approval under rule 7.1
Nil
6dNumber of +securities issued with security holder approval under rule 7.1A
Nil
6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
Nil
6f Number of securities issued under an exception in rule 7.2
N/A
6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
N/A
6h If securities were issued under rule 7.1A for non-‐cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
Refer to the attached Annexure 1
6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements
21 March 2017
Dates of entering +securities into uncertificated holdings or despatch of certificates
Number
+Class
936,369,109
Fully Paid Ordinary Shares
(RNO)
203,150,000
Listed Options (RNOOA)
exercisable at $0.06 per
option on or before 30 April
2017
Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)
Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)
Number
+Class (Options over Ordinary Shares)
Amount
Exercise Price
Expiration Date
ASX Code
769,230
$0.065
30 April 2019
40,000,000
$0.065
30 April 2017
10,000,000
$0.0674
30 April 2019
18,000,000
$0.065
11 April 2019
68,769,230
Total
Unchanged
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
Rhinomed Limited published this content on 21 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 March 2017 05:48:15 UTC.
Original documenthttp://www.rhinomed.global/wp-content/uploads/2017/03/Appendix-3B.pdf
Public permalinkhttp://www.publicnow.com/view/FC2A1FA903558DC48BE56273A8F9C1713500A4DF